Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 6Myeloid 3CNS 2Gastrointestinal 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Oxaliplatin 197Bevacizumab 161Fluorouracil 154Capecitabine 137Gemcitabine 134Leucovorin 111pembrolizumab 99Cisplatin 94Drug Therapy 89Irinotecan 80Radiotherapy 73sintilimab 70130-nm albumin-bound paclitaxel 66durvalumab 65Paclitaxel 64Specimen Handling 62Cetuximab 61lenvatinib 59tislelizumab 58Nivolumab 55Magnetic Resonance Spectroscopy 55Folfox protocol 55Blood Specimen Collection 52atezolizumab 47Biopsy 46Surgical Procedures, Operative 40Taxes 39Albumin-Bound Paclitaxel 39Immune Checkpoint Inhibitors 37HMPL-013 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × olutasidenib × Gastrointestinal × Clear all
NCT07486713 2026-03-20

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡